Added value of digital PET/CT in (re)staging patients with pancreatic cancer

Added value of digital PET/CT in (re)staging patients with pancreatic cancer - (Re)stadiering of digital PET in pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46552

Enrollment

Registered

2018-03-19

Start date

2018-09-13

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the pancreas pancreatic cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: • Histological or cytological confirmed malignant peri-ampullary tumour, resectable or borderline resectable, without evidence of distant metastases. • Inclusion in the Preopanc-2 study and randomized for neo-adjuvant chemotherapy • Written informed consent There is an additional inclusion criterion for the acquisition of the second FDG-PET/CT scan: only patients that are treated with at least 4 cycles, and a maximum of 8 cycles of neo-adjuvant chemotherapy will be referred for this FDG-PET/CT scan.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Age

Design outcomes

Primary

Measure	Time frame
Diagnostic value (sensitivity, specificity, accuracy) of digital PET/CT for staging and response assessment	—

Secondary

Measure	Time frame
Correlation of staging data and restaging data with tumor marker CA 19.9 serum levels.	—

Countries

Netherlands

Outcome results